Eyepoint Pharmaceuticals Inc., Investment Losses
The White Law Group is investigating potential securities claims involving broker-dealers who may have unsuitably recommended Eyepoint Pharmaceuticals Inc., to investors.
EyePoint Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology, according to MarketWatch.
According to MarketWatch, as of November 15, 2020, the share price of Eyepoint Pharmaceuticals Inc. has dropped more than -60% in the past year.
The problem with pharmaceutical and biotech investments such as Eyepoint Pharmaceuticals, Inc., is that they typically involve a high degree of risk. The research and development process for pharma companies often involves costly and lengthy testing trials that yield specific data. If the expected data or end points are not met, that could be bad news for investors.
Broker dealers are required to perform adequate due diligence on any investment they recommend and to ensure that all recommendations are suitable for the investor. Firms that fail to do so, may be held responsible for any losses in a FINRA arbitration claim.
